Simultaneous determination of phenylbutazone and its metabolites in plasma and urine by high-performance liquid chromatography.
A high-performance liquid chromatographic method was developed for the simultaneous determination of phenylbutazone and its metabolites, oxyphenbutazone and gamma-hydroxy-phenylbutazone, in plasma and urine. Samples were acidified with hydrochloric acid and extracted with benzene--cyclohexane (1:1, v/v). The extract was redissolved in methanol and chromatographed on a muBondapak C18 column using a mobile phase of methanol--0.01 M sodium acetate buffer (pH 4.0) in a linear gradient (50 to 100% methanol at 5% min; flow-rate 2.0 ml/min) in a high-performance liquid chromatograph equipped with an ultraviolet absorbance detector (254 nm). The detection limit for phenylbutazone, oxyphenbutazone and for gamma-hydroxyphenylbutazone was 0.05 microgram/ml. A precise and sensitive assay for the determination of phenylbutazone and its metabolites was established.
D000818:Animals; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004285:Dogs; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007700:Kinetics; D008297:Male; D010113:Oxyphenbutazone / Q000097:blood* / Q000652:urine; D010653:Phenylbutazone / Q000031:analogs & derivatives* / Q000097:blood* / Q000652:urine; D051381:Rats
C008072:gamma-hydroxyphenylbutazone; D010653:Phenylbutazone; D010113:Oxyphenbutazone